HUTCHMED (China) Limited (AIM:HCM)
215.00
+12.00 (5.91%)
Oct 12, 2026, 4:35 PM GMT
HUTCHMED (China) Revenue
HUTCHMED (China) had revenue of $278.29M USD in the half year ending June 30, 2026, a decrease of -8.96%. This brings the company's revenue in the last twelve months to $549.12M, down -8.81% year-over-year. In the year 2025, HUTCHMED (China) had annual revenue of $548.51M, down -12.96%. That makes HUTCHMED (China) the 10,722nd largest company in the world by revenue and 264th in the United Kingdom.
Revenue (ttm)
$549.12M
Revenue Growth
-8.81%
P/S Ratio
4.26
Revenue / Employee
$306.77K
Employees
1,790
Market Cap
1.87B GBP
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 548.51M | -81.69M | -12.96% |
| Dec 31, 2024 | 630.20M | -207.80M | -24.80% |
| Dec 31, 2023 | 838.00M | 411.59M | 96.52% |
| Dec 31, 2022 | 426.41M | 70.28M | 19.73% |
| Dec 31, 2021 | 356.13M | 128.15M | 56.21% |
| Dec 31, 2020 | 227.98M | 23.09M | 11.27% |
| Dec 31, 2019 | 204.89M | -9.22M | -4.31% |
| Dec 31, 2018 | 214.11M | -27.09M | -11.23% |
| Dec 31, 2017 | 241.20M | 25.12M | 11.63% |
| Dec 31, 2016 | 216.08M | 37.88M | 21.25% |
| Dec 31, 2015 | 178.20M | 90.87M | 104.06% |
| Dec 31, 2014 | 87.33M | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Haleon | 11.15B |
| Hikma Pharmaceuticals | 2.58B |
| ECO Animal Health Group | 87.53M |
| Allergy Therapeutics | 57.29M |
| Shield Therapeutics | 44.19M |
| Provexis | 1.26M |
| Chill Brands Group | 955.18K |
HUTCHMED (China) News
- 2 days ago - HUTCHMED (China) Ltd (HCM) Stock Up 3.1% but GF Value Says Overvalued -- GF Score: 78/100 - GuruFocus
- 3 days ago - HUTCHMED (China) Ltd (HCM) Shares Fall 4.3% -- What GF Score of 77 Tells Investors - GuruFocus
- 11 days ago - HUTCHMED (China) Ltd (HCM) Shares Surge 3.4% -- What GF Score of 79 Tells Investors - GuruFocus
- 13 days ago - HUTCHMED Seeks FDA Approval For ORPATHYS-TAGRISSO In Resistant Lung Cancer - Nasdaq
- 13 days ago - AstraZeneca files US FDA application for HUTCHMED lung cancer drug combination - Reuters
- 13 days ago - Hutchmed says AstraZeneca submits NDA for ORPATHYS+TAGRISSO in NSCLC - TheFly
- 13 days ago - HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer - GlobeNewsWire
- 14 days ago - Hutchmed (HCM) Launches Phase Ia Trial for HMPL-A830 in Advanced Solid Tumors - GuruFocus